MA29378B1 - Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer - Google Patents

Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer

Info

Publication number
MA29378B1
MA29378B1 MA30267A MA30267A MA29378B1 MA 29378 B1 MA29378 B1 MA 29378B1 MA 30267 A MA30267 A MA 30267A MA 30267 A MA30267 A MA 30267A MA 29378 B1 MA29378 B1 MA 29378B1
Authority
MA
Morocco
Prior art keywords
cancer
treatment
pharmaceutical composition
diphenyluree
carboxyaryl
Prior art date
Application number
MA30267A
Other languages
English (en)
Inventor
Fritz Schueckler
Axel Wollenschlaeger
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36507604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29378(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA29378B1 publication Critical patent/MA29378B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE QUI COMPREND LE COMPOSÉ DE LA FORMULE (I) À UNE CONCENTRATION ÉLEVÉE ET AU MOINS UN EXCIPIENT PHARMACEUTIQUEMENT ACCEPTABLE, L'UTILISATION DE LA COMPOSITION POUR LE TRAITEMENT DE MALADIES HYPERPROLIFÉRATIVES, TELLES QUE LE CANCER, SOIT COMME SEUL AGENT OU EN COMBINAISON AVEC D¿AUTRES THÉRAPIES ANTICANCÉREUSES, AINSI QUE LE PROCÉDÉ DE PRÉPARATION DE LADITE COMPOSITION.
MA30267A 2005-03-07 2007-10-02 Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer MA29378B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65882705P 2005-03-07 2005-03-07

Publications (1)

Publication Number Publication Date
MA29378B1 true MA29378B1 (fr) 2008-04-01

Family

ID=36507604

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30267A MA29378B1 (fr) 2005-03-07 2007-10-02 Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer

Country Status (38)

Country Link
US (2) US9737488B2 (fr)
EP (1) EP1868579B1 (fr)
JP (1) JP5304241B2 (fr)
KR (1) KR101335932B1 (fr)
CN (2) CN101132779B (fr)
AR (1) AR054234A1 (fr)
AT (1) ATE482693T1 (fr)
AU (1) AU2006222365B2 (fr)
BR (1) BRPI0608840B8 (fr)
CA (1) CA2601955C (fr)
CR (1) CR9348A (fr)
CU (1) CU23821A3 (fr)
CY (1) CY1111065T1 (fr)
DE (1) DE602006017188D1 (fr)
DK (1) DK1868579T3 (fr)
DO (1) DOP2006000057A (fr)
ES (1) ES2351612T3 (fr)
GT (1) GT200600096A (fr)
HK (1) HK1209620A1 (fr)
HN (1) HN2006009702A (fr)
HR (1) HRP20100674T1 (fr)
IL (1) IL185517A (fr)
MA (1) MA29378B1 (fr)
MX (1) MX2007010856A (fr)
MY (1) MY162319A (fr)
NO (1) NO343834B1 (fr)
NZ (1) NZ561178A (fr)
PE (1) PE20061345A1 (fr)
PL (1) PL1868579T3 (fr)
PT (1) PT1868579E (fr)
SG (1) SG160364A1 (fr)
SI (1) SI1868579T1 (fr)
TN (1) TNSN07341A1 (fr)
TW (1) TWI324928B (fr)
UA (1) UA93673C2 (fr)
UY (1) UY29410A1 (fr)
WO (1) WO2006094626A1 (fr)
ZA (1) ZA200707638B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (fr) 1999-01-13 2013-10-08 Bayer Healthcare Llc Diphenyle urees a substitution .omega.-carboxy aryle en tant qu'inhibiteurs de la kinase p38
EP2324825A1 (fr) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylurées dotées d'une activité d'inhibition de l'angiogenèse
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
WO2006034797A1 (fr) * 2004-09-29 2006-04-06 Bayer Healthcare Ag Forme thermodynamiquement stable de tosylate de bay 43-9006
KR101335932B1 (ko) 2005-03-07 2013-12-04 바이엘 헬스케어 엘엘씨 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
EP2289515A3 (fr) * 2005-10-31 2012-04-11 Bayer HealthCare LLC Combinaison contenant une diaryl urée et un interferon
CA2657379A1 (fr) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Formulations de sorafenib nanoparticulaire
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008089389A2 (fr) 2007-01-19 2008-07-24 Bayer Healthcare Llc Traitement de cancers à résistance acquise aux inhibiteurs kit
WO2009106825A1 (fr) * 2008-02-27 2009-09-03 Cipla Limited Polymorphes de sorafénib et leurs sels
HUE055911T2 (hu) 2008-05-15 2021-12-28 Celgene Corp Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
EP2440531A2 (fr) * 2009-06-12 2012-04-18 Ratiopharm GmbH Polymorphes de 4-[4-[[4-chloro-3-(trifluorométhyl)phényl]carbamoylamino]phénoxy]-n-méthyl-pyridine-2-carboxamide
EP2528899B1 (fr) 2010-01-29 2014-10-15 Ranbaxy Laboratories Limited Solvate de diméthylsulfoxyde du sorafenib
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
EP2621486A1 (fr) 2010-10-01 2013-08-07 Bayer Intellectual Property GmbH Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
EP2559431A1 (fr) 2011-08-17 2013-02-20 Ratiopharm GmbH Composition pharmaceutique comportant du 4-[4-[[4-Chloro-3-(trifluoromethyl)phényl]carbamoylamino]phénoxy]-N-méthyl-pyridine-2-carboxamide
WO2013110644A1 (fr) 2012-01-23 2013-08-01 Sandoz Ag Composition pharmaceutique contenant du tosylate de sorafénib cristallin
WO2013184572A1 (fr) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
WO2016182867A1 (fr) * 2015-05-14 2016-11-17 Fmc Corporation Procédé de fabrication de cellulose microcristalline blanchie
TWI781922B (zh) * 2016-03-14 2022-11-01 日商參天製藥股份有限公司 由葡甲胺或其鹽構成之防腐劑
JP6739289B2 (ja) * 2016-08-25 2020-08-12 日本化薬株式会社 ゲフィチニブを有効成分とする医薬錠剤の製造方法
CN106344530B (zh) * 2016-09-30 2019-03-19 京津冀联创药物研究（北京）有限公司 一种索拉非尼组合物及其制备方法
EP3630078B1 (fr) 2017-05-26 2024-09-11 Bruin Biosciences, Inc. Agents pour chimio-embolisation
US11179322B2 (en) 2018-07-10 2021-11-23 Novocure Gmbh Methods and compositions for treating tumors with TTFields and sorafenib
WO2018211336A2 (fr) 2018-09-07 2018-11-22 Alvogen Malta Operations (Row) Ltd Forme galénique solide contenant du tosylate de sorafénib
US12240869B2 (en) 2018-11-01 2025-03-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP4725489A2 (fr) 2019-08-02 2026-04-15 OneHealthCompany, Inc. Traitement de cancers canins
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125359A (en) * 1964-03-17 Push-pull breakaway coupling
NL282262A (fr) * 1961-11-08
AU594098B2 (en) 1985-12-11 1990-03-01 Ishihara Sangyo Kaisha Ltd. N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation
DK607188A (da) 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
US5773459A (en) 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
EP0841910A4 (fr) 1995-07-25 2006-09-13 Smithkline Beecham Corp INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE
CZ298463B6 (cs) 1996-04-23 2007-10-10 Vertex Pharmaceuticals Incorporated Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
ES2153337T3 (es) 1997-05-23 2008-11-01 Bayer Pharmaceuticals Corporation Inhibidores de la quinasa raf.
AU7585498A (en) 1997-05-23 1998-12-11 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US7329670B1 (en) * 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
WO1999032110A1 (fr) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION DE L'ACTIVITE DE p38 KINASE AU MOYEN D'UREES HETEROCYCLIQUES ARYLE ET HETEROARYLE SUBSTITUEES
SK285371B6 (sk) 1997-12-22 2006-12-07 Bayer Corporation Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
HUP0101704A3 (en) 1997-12-22 2002-12-28 Bayer Corp Pittsburgh Kinease substituted heterocyclic ureas with raf inhibition activity and pharmaceutical compositions containing them
WO1999032463A1 (fr) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION DE LA KINASE p38 PAR DES DIPHENYL-UREES SYMETRIQUES ET DISSYMETRIQUES
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
EP1049664B1 (fr) 1997-12-22 2005-03-16 Bayer Pharmaceuticals Corporation Inhibition de raf kinase au moyen de diphenylurees substituees symetriques et asymetriques
ES2154253T3 (es) 1997-12-22 2012-01-27 Bayer Healthcare Llc Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas.
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US20030087849A1 (en) 2001-07-03 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of HKR1 expression
US6117451A (en) 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
CA2359244C (fr) 1999-01-13 2013-10-08 Bayer Healthcare Llc Diphenyle urees a substitution .omega.-carboxy aryle en tant qu'inhibiteurs de la kinase p38
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US20020065296A1 (en) * 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (fr) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
CA2361057C (fr) * 1999-01-22 2010-04-06 Kazuo Kubo Derives de quinoline et derives de quinazoline
EP1309315B1 (fr) * 2000-08-18 2006-06-14 Pharmacia Corporation Preparation orale a desintegration rapide de valdecoxib
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
TWI336328B (en) 2001-03-23 2011-01-21 Bayer Healthcare Llc Rho-kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
ATE355272T1 (de) 2001-04-20 2006-03-15 Bayer Pharmaceuticals Corp Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe
US20030207914A1 (en) * 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
AU2002351196A1 (en) 2001-12-03 2003-06-17 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
AU2002365899B2 (en) 2001-12-04 2007-09-13 Onyx Pharmaceuticals, Inc. RAF-MEK-ERK pathway inhibitors to treat cancer
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
SI1580188T1 (sl) 2002-02-11 2012-02-29 Bayer Healthcare Llc Aril sečnine kot kinazni inhibitorji
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
EP2324825A1 (fr) * 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylurées dotées d'une activité d'inhibition de l'angiogenèse
WO2003068223A1 (fr) 2002-02-11 2003-08-21 Bayer Corporation Urees aryliques a kinase de raf et activite inhibitrice d'angiogenese
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
CA2516627A1 (fr) 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Derives de pyridine substitues utilises pour traiter des cancers et d'autres troubles
JP5229853B2 (ja) 2003-02-28 2013-07-03 ニッポネックス インコーポレイテッド 癌その他の疾患の治療に有用な新規な二環尿素誘導体
CN1839126A (zh) 2003-02-28 2006-09-27 拜耳制药公司 用于治疗癌症和其它病症的新的氰基吡啶衍生物
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
US6896863B2 (en) * 2003-04-01 2005-05-24 E. I. Du Pont De Nemours And Company Sodium cyanide process
DE602004007382T2 (de) * 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
US20060234931A1 (en) * 2003-07-17 2006-10-19 Biggs William H Iii Treatment of diseases with kinase inhibitors
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
US20080085902A1 (en) * 2003-09-23 2008-04-10 Guido Bold Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
US7552093B2 (en) * 2003-12-04 2009-06-23 Black Duck Software, Inc. Resolving license dependencies for aggregations of legally-protectable content
EP1694865A4 (fr) 2003-12-12 2007-06-06 Bayer Pharmaceuticals Corp Procede de prediction et de pronostic du cancer, et surveillance de traitement anticancereux
JP2007535565A (ja) * 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体
BRPI0512567A (pt) 2004-06-22 2008-03-25 Pfizer Prod Inc compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CN101048140B (zh) 2004-08-27 2013-06-19 拜尔保健公司 用于治疗癌症的药物组合物
WO2006034797A1 (fr) 2004-09-29 2006-04-06 Bayer Healthcare Ag Forme thermodynamiquement stable de tosylate de bay 43-9006
SG155997A1 (en) 2004-09-29 2009-10-29 Bayer Schering Pharma Ag Process for the preparation of 4-{4-[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n- methylpyridine-2-carboxamide
KR101335932B1 (ko) 2005-03-07 2013-12-04 바이엘 헬스케어 엘엘씨 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
MX2007014726A (es) 2005-05-27 2008-02-14 Bayer Healthcare Ag Tratamiento combinado que comprende un compuesto diarilurea y una pi3, akt cinasa o inhibidores mtor (rapamicina) para tratamiento de cancer.
AU2006251428A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
US20080305962A1 (en) 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
EP1946115A4 (fr) 2005-10-21 2009-12-02 Bayer Healthcare Llc Méthodes de prévision et de pronostic du cancer, et surveillance d'une thérapie anticancéreuse
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
EP2289515A3 (fr) * 2005-10-31 2012-04-11 Bayer HealthCare LLC Combinaison contenant une diaryl urée et un interferon
JP2009513706A (ja) * 2005-10-31 2009-04-02 バイエル ヘルスケア リミティド ライアビリティ カンパニー ソラフェニブを用いた癌の治療
CN101351708A (zh) * 2005-11-02 2009-01-21 拜尔健康护理有限责任公司 癌症的预测和预后以及监控癌症治疗的方法
RU2008121751A (ru) * 2005-11-02 2009-12-20 БАЙЕР ХЕЛСКЕР ЛЛСи (US) Способы прогнозирования и предсказания рака и мониторинг терапии раковых заболеваний
PL1948176T3 (pl) 2005-11-10 2011-05-31 Bayer Schering Pharma Ag Diarylomoczniki do leczenia nadciśnienia płucnego
JP2009515978A (ja) 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー Ｋｉｔ阻害剤に対する獲得耐性を伴う癌の治療
RU2008123406A (ru) * 2005-11-14 2009-12-27 Байер Хелскеа эЛэЛСи (US) Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента
WO2007059155A1 (fr) 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Traitement de cancers a resistance a des agents chimiotherapeutiques
US20110195110A1 (en) 2005-12-01 2011-08-11 Roger Smith Urea compounds useful in the treatment of cancer
US20090227637A1 (en) * 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
EP2111401B1 (fr) 2006-12-20 2011-02-16 Bayer HealthCare, LLC 4- {4-[({3- tert- butyl-1- [3- (hydroxymethyl) phenyl]- 1h- pyrazol- 5- yl } carbamoyl) -amino]- 3- fluorophenoxy} - n- methylpyridine- 2- carboxamide ainsi que des promédicaments et des sels de ceux-ci utilisés pour traiter un cancer
WO2008089389A2 (fr) 2007-01-19 2008-07-24 Bayer Healthcare Llc Traitement de cancers à résistance acquise aux inhibiteurs kit
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CA2840491A1 (fr) 2011-06-28 2013-01-03 Bayer Healthcare Llc Composition pharmaceutique topique ophtalmologique contenant du sorafenib
EP2559431A1 (fr) 2011-08-17 2013-02-20 Ratiopharm GmbH Composition pharmaceutique comportant du 4-[4-[[4-Chloro-3-(trifluoromethyl)phényl]carbamoylamino]phénoxy]-N-méthyl-pyridine-2-carboxamide

Also Published As

Publication number Publication date
BRPI0608840B1 (pt) 2020-04-14
PL1868579T3 (pl) 2011-03-31
CA2601955A1 (fr) 2006-09-14
US20080242707A1 (en) 2008-10-02
DE602006017188D1 (de) 2010-11-11
CN101132779A (zh) 2008-02-27
DOP2006000057A (es) 2006-09-30
CU23821A3 (es) 2012-06-21
PE20061345A1 (es) 2007-01-28
ES2351612T3 (es) 2011-02-08
GT200600096A (es) 2007-01-12
CN101132779B (zh) 2016-03-16
CR9348A (es) 2008-02-13
MY162319A (en) 2017-05-31
TW200700093A (en) 2007-01-01
TWI324928B (en) 2010-05-21
NZ561178A (en) 2010-11-26
WO2006094626A1 (fr) 2006-09-14
HK1118019A1 (zh) 2009-01-30
NO343834B1 (no) 2019-06-17
TNSN07341A1 (en) 2008-12-31
CY1111065T1 (el) 2015-06-11
ZA200707638B (en) 2009-08-26
KR101335932B1 (ko) 2013-12-04
AR054234A1 (es) 2007-06-13
BRPI0608840A2 (pt) 2010-02-02
ATE482693T1 (de) 2010-10-15
UA93673C2 (ru) 2011-03-10
SG160364A1 (en) 2010-04-29
AU2006222365B2 (en) 2011-07-14
RU2007136896A (ru) 2009-04-20
MX2007010856A (es) 2007-11-12
IL185517A0 (en) 2008-01-06
HK1209620A1 (en) 2016-04-08
EP1868579A1 (fr) 2007-12-26
UY29410A1 (es) 2006-10-31
AU2006222365A1 (en) 2006-09-14
NO20075042L (no) 2007-10-05
CU20070203A7 (es) 2010-01-22
BRPI0608840B8 (pt) 2021-05-25
US20180036249A1 (en) 2018-02-08
KR20070111513A (ko) 2007-11-21
HN2006009702A (es) 2010-06-08
HRP20100674T1 (hr) 2011-01-31
JP2008531741A (ja) 2008-08-14
CA2601955C (fr) 2012-07-10
RU2420283C2 (ru) 2011-06-10
CN104688697A (zh) 2015-06-10
JP5304241B2 (ja) 2013-10-02
US9737488B2 (en) 2017-08-22
SI1868579T1 (sl) 2011-02-28
PT1868579E (pt) 2010-12-03
DK1868579T3 (da) 2011-01-10
IL185517A (en) 2016-05-31
EP1868579B1 (fr) 2010-09-29

Similar Documents

Publication Publication Date Title
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
MA47399B1 (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA33768B1 (fr) Triazolopyridines
MA29543B1 (fr) Procedes pour traiter un cancer pharmacoresistant
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA27427A1 (fr) Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
WO2001081310A8 (fr) 1-aroyle-piperidinyle benzamidines
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
ATE449081T1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
MY145074A (en) Thiazolidin-4-one derivatives
MA30604B1 (fr) Agonistes de ep2
MA29723B1 (fr) Composes
MA29451B1 (fr) Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme
MA29969B1 (fr) Formulations de quinolinones